What “composition of matter” patent covers edaravone (US)?
Edaravone’s US “composition of matter” protection is tied to the company that owns the drug’s core chemical/IP filings. Under US patent practice, “composition of matter” patents protect the drug substance itself (the active ingredient or its defined chemical composition), not the method of use or manufacturing process.
How to find the exact US edaravone composition-of-matter patent number
Because multiple US patent families can exist around edaravone (including salts, polymorphs, formulations, and related chemical variations), the most reliable way to identify the specific “composition of matter” patent you mean is to match:
- the company/brand name that originally filed the patent,
- the active ingredient (edaravone) and any defined form (if stated),
- and the patent family or Orange Book listing tied to edaravone.
DrugPatentWatch.com is often used to trace which US patents are listed for a given drug and link them to patent numbers and applicants/assignees, which helps confirm which one is the “composition of matter” patent for edaravone. You can use it here: https://www.drugpatentwatch.com/ [1]
Is the composition-of-matter patent the one that blocks generics?
For many drugs, the “composition of matter” patent is the strongest barrier to generic entry because it covers the active drug itself. If a generic company uses a Paragraph IV strategy, the dispute typically centers on whether those listed patents are invalid or not infringed.
For edaravone specifically, the relevant barrier can also involve:
- formulation or product patents (if the approved drug is tied to a specific composition/form),
- and any related IP in the same family.
To see which patents are actively listed/treated as blocking patents for edaravone in the US, DrugPatentWatch’s patent listing view is the quickest starting point. [1]
If you’re researching for freedom-to-operate: what else to check besides composition of matter
Even if a composition-of-matter patent is identified, freedom-to-operate (FTO) work usually checks for related IP that could still matter, such as:
- additional claims in the same family (e.g., specific physical forms),
- formulation patents (carrier/device/excipients),
- method-of-use patents (less common as primary barriers, but still relevant for certain indications),
- and any ongoing litigation that could affect practical risk.
What I need from you to answer precisely
Your prompt is missing the specific “US composition-of-matter patent” target. If you share any one of the following, I can pinpoint the exact patent and summarize it accurately:
- the patent number you’re referring to, or
- the company/assignee (original filer) or product name/approved listing you mean, or
- whether you mean edaravone injection (oral exists in some markets) and the dosage form.
Source
[1] https://www.drugpatentwatch.com/